Biomedical Engineering Reference
In-Depth Information
of published double-blind, placebo-controlled clinical trials. Clin Ther 2000;
22(2):209-221.
97. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic
obstructive pulmonary disease: systematic review. BMJ 2001; 322(7297):
1271-1274.
98. Grandjean EM, Berthet PH, Ruffmann R, Leuenberger P. Cost-effectiveness
analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchi-
tis. Pharmacol Res 2000; 42(l):39-50.
99. McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of
dornase alfa in patients with advanced cystic fibrosis lung disease, Pulmozyme
Study Group. Chest 1996; 110(4):889-895.
100. Rubin BK. Physiology of Airway Mucus Clearance. Respir Care 2002;
47(7):761-768.
101. Rubin BK. The pharmacologic approach to airway clearance: mucoactive
agents. Respir Care 2002; 47(7):818-822.
102. Rhee CS, Majima Y, Arima S, Jung HW, Jinn TH, Min YG, et al. Effects of
clarithromycin on rheological properties of nasal mucus in patients with
chronic sinusitis. Ann Otol Rhinol Laryngol 2000; 109(5):484-487.
103. Suez D, Szefler SJ. Excessive accumulation of mucus in children with asthma:
a potential role for erythromycin? A case discussion. J Allergy Clin Immunol
1986; 77(2):330-334.
104. Marom ZM, Goswami SK. Respiratory mucus hypersecretion (bronchor-
rhea): a case discussion—possible mechanisms(s) and treatment. J Allergy Clin
Immunol 1991; 87(6):1050-1055.
105. Shibuya Y, Wills PJ, Cole PJ. The effect of erythromycin on mucociliary
transportability and rheology of cystic fibrosis and bronchiectasis sputum.
Respiration 2001; 68(6):615-619.
106. Gorrini M, Lupi A, Viglio S, Pamparana F, Cetta G, Iadarola P, et al. Inhibi-
tion of human neutrophil elastase by erythromycin and flurythromycin, two
macrolide antibiotics. Am J Respir Cell Mol Biol 2001; 25(4):492-499.
107. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro
effects of macrolide antibiotics on mucus secretion in airway epithelial cells.
Am J Respir Crit Care Med 2003; 168(5):581-587.
108. Barnes PJ. Current and future therapies for airway mucus hypersecretion.
Novartis Found Symp 2002; 248:237-249.
109. Rogers DF. Mucus hypersecretion in COPD. Hansel TT, Barnes PJ, eds.
Recent Advances in the Pathophysiology of COPD. Basel: Birkh¨user Verlag,
2004:101-119.
110. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol
Chem 2001; 276(39):36059-36062.
111. Tesfaigzi Y, Kluger M, Kozak W. Clinical and cellular effects of cytochrome
P-450 modulators. Respir Physiol 2001; 128(l):79-87.
112. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J
Pharmacol 2001; 429(1-3):195-207.
113. Montuschi P, Kharitonov SA, Barnes PJ. Exhaled carbon monoxide and
nitric oxide in COPD. Chest 2001; 120(2):496-501.
